Last reviewed · How we verify
NCT03119636
A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's Disease
Phase 1/Phase 2 trial testing NPC transplantation in Parkinson's Disease in 50 participants. Status unknown.
1 November 2018
Quick facts
| Lead sponsor | Chinese Academy of Sciences |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 May 2017 |
| Primary completion | 1 November 2018 |
| Estimated completion | 1 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- NPC transplantation — full drug profile →
- Levodopa (LEVODOPA) — full drug profile →
Conditions studied
- Parkinson's Disease — all drugs for Parkinson's Disease →
Sponsor
Chinese Academy of Sciences — full company profile →
Who can join
Adults 50 to 80, any sex, with Parkinson's Disease. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Incidence of treatment-emergent adverse events (TEAEs), severe TEAEs as assessed by head MRI and blood examination
Time frame: 6 months
Number of subjects with adverse events such as the evidence of graft failure or rejection
Sponsor's own description
This study will evaluate the safety and efficacy of intracerebral transplantation of human embryonic stem cells-derived neural precursor cells in patients with Parkinson's Disease.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease.
Doi D, Magotani H, Kikuchi T, Ikeda M, et al · · 2020 · cited 257× · PMID 32632153 · DOI 10.1038/s41467-020-17165-w -
Induced Pluripotent Stem Cells (iPSCs)-Roles in Regenerative Therapies, Disease Modelling and Drug Screening.
Aboul-Soud MAM, Alzahrani AJ, Mahmoud A. · · 2021 · cited 137× · PMID 34571968 · DOI 10.3390/cells10092319 -
iPS cell-based therapy for Parkinson's disease: A Kyoto trial.
Takahashi J. · · 2020 · cited 129× · PMID 33490319 · DOI 10.1016/j.reth.2020.06.002 -
Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis.
Deinsberger J, Reisinger D, Weber B. · · 2020 · cited 109× · PMID 32983575 · DOI 10.1038/s41536-020-00100-4 -
Immunological considerations and challenges for regenerative cellular therapies.
Petrus-Reurer S, Romano M, Howlett S, Jones JL, et al · · 2021 · cited 97× · PMID 34172826 · DOI 10.1038/s42003-021-02237-4 -
Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease.
Wang YK, Zhu WW, Wu MH, Wu YH, et al · · 2018 · cited 87× · PMID 29910127 · DOI 10.1016/j.stemcr.2018.05.010 -
Recent developments in the treatment of Parkinson's Disease.
Stoker TB, Barker RA. · · 2020 · cited 85× · PMID 32789002 · DOI 10.12688/f1000research.25634.1 -
Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives.
Rahimi Darehbagh R, Seyedoshohadaei SA, Ramezani R, Rezaei N. · · 2024 · cited 84× · PMID 39054501 · DOI 10.1186/s40001-024-01987-1
Verify or expand the search:
- PubMed search for NCT03119636
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson's Disease
Currently open trials in the same condition.
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
- NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
- NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
- NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting
Other Chinese Academy of Sciences trials
Trials by the same sponsor.
- NCT07170345 — Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion · recruiting
- NCT07158372 — Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning · recruiting
- NCT06989177 — Probiotic Intervention on Body Weight · NA · recruiting
- NCT06989203 — Protein Supplementation Intervention on Body Weight · NA · recruiting
- NCT06035250 — AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03119636 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Sciences
- Last refreshed: 13 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03119636.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing